Main content

    Skin Cancer Clinical Trials

    CPMC Cancer ServicesOpens new window | CPMC Center for Melanoma Research and TreatmentOpens new window


    Oncology / Cancer Clinical Trials Main Page | Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at ClinicalTrials.gov


    Active Trials (Melanoma)

    Title: Phase 1b/2, Multicenter, Open-label Trial to Evaluate the Safety and Efficacy of Talimogene Laherparepvec and Ipilimumab Compared to Ipilimumab Alone in Subjects With Previously Untreated, Unresectable, Stage IIIb-IV Melanoma
    Description: Ipilimumab With or Without Talimogene Laherparepvec in Unresectable Melanoma
    Investigator (CPMC): Kevin Kim, MD
    Investigator (Santa Rosa): Peter Brett, MD
    Eligibility: Subjects, 18 y/o and older, with histologically confirmed diagnosis of malignant melanoma
    Status: Active and open to enrollment
    Contact (CPMC): Ron Frianeza, 415-600-3027, Email: FrianeR@cpmcri.org about Study Amgen TVEC
    Contact (Santa Rosa): Christina DeVisser, 707-576-4739, Email: DevissC@cpmcri.org about Study Amgen TVEC

    Title: Expanded Access Program With Nivolumab (BMS-936558) in Combination With Ipilimumab (Yervoy®) in Anti-CTLA-4 Treatment-Naïve Subjects With Unresectable or Metastatic Melanoma
    Description: The purpose of this study is to provide treatment with Nivolumab in combination with Ipilimumab and to assess the safety and tolerability of this combination in subjects who are anti-cytotoxic T lymphocyte associated antigen (CTLA)-4 treatment-naive and have unresectable or metastatic melanoma
    Eligibility: Subjects, 18 y/o and older with histologically confirmed stage III (unresectable) or stage IV melanoma, as per American Joint Committee on Cancer (AJCC) 2010 staging system, including mucosal melanoma
    Investigator: Kevin Kim, MD
    Status: Active and open to enrollment
    Contact: Ron Frianeza, 415-600-3027, Email: FrianeR@cpmcri.org about Study BMS CA209-218

    Title: A Phase Ib/II, Multicenter, Open Label, Study of LEE011 in Combination With MEK162 in Adult Patients With NRAS Mutant Melanoma
    Description: A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma
    Eligibility: Subjects, 18 y/o and older. Patients enrolled into phase Ib may be enrolled with evaluable disease only. Patients enrolled into the phase II expansion must have at least one measurable lesion as defined by RECIST 1.1 criteria for solid tumors
    Investigator: Kevin Kim, MD
    Status: Coming soon
    Contact: Ron Frianeza, 415-600-3027, Email: FrianeR@cpmcri.org about Study Novartis CMEK162X2114

    Title: A Phase 2, Multicenter, Randomized, Open-label Trial Assessing the Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Resectable, Stage IIIB to IVM1a Melanoma
    Description: This is a phase 2, multicenter, randomized, open-label study to estimate the efficacy of talimogene laherparepvec as a neoadjuvant treatment followed by surgery compared to surgery alone in subjects with completely resectable stage IIIB, IIIC, or IVM1a melanoma
    Investigator: Kevin Kim, MD
    Eligibility: Subjects, 18 y/o and older with a histologically confirmed diagnosis of stage IIIB, IIIC or IVM1a melanoma eligible for complete surgical resection
    Status: Active and open to enrollment
    Contact: Ron Frianeza, 415-600-3027, Email: FrianeR@cpmcri.org about Study TVEC 20110266

    Title: A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy With Nivolumab Versus Ipilimumab After Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects Who Are at High Risk for Recurrence
    Description: (CheckMate 238: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 238) The purpose of this study is to determine whether nivolumab is better than ipilimumab to prevent recurrence of melanoma
    Investigator: Kevin Kim, MD
    Eligibility: Subjects, 18 y/o and older who have had a completely removed melanoma by surgery performed within 12 weeks of randomization, Stage IIIb/C or Stage IV before complete resection and no previous anti-cancer treatment
    Status: Active and open to enrollment
    Contact: Laurel Brechtel, 415-600-1654, Email: BrechtLA@cpmcri.org about Study BMS CA 209-238

    Title: Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
    Description: This phase I/II trial studies the side effects and the best dose of Akt inhibitor GSK2141795 (GSK2141795) when given together with dabrafenib and trametinib and to see how well they work in treating patients with stage IIIC-IV cancer
    Investigator: NCI - National Cancer Institute
    Eligibility: Subjects, 18 y/o and older who have BRAF^V600 mutant metastatic cancer irrespective of the histology or prior therapy
    Status: Active and open to enrollment
    Contact: Laurel Brechtel, 415-600-1654, Email: BrechtLA@cpmcri.org about Study SWOG S1221

    Title: A Multi-Center Phase 2 Open-Label Study to Evaluate Safety and Efficacy in Subjects With Melanoma Metastatic to the Brain Treated With Nivolumab in Combination With Ipilimumab Followed by Nivolumab Monotherapy
    Description: This is an open-label, multi-site Phase 2 study of Nivolumab combined with Ipilimumab followed by Nivolumab monotherapy for the treatment of subjects with Melanoma metastatic to the brain
    Investigator: Kevin Kim, MD
    Eligibility: Subjects, 18 y/o and older who have histologically confirmed malignant melanoma with measurable metastases in both brain and extracranial compartments
    Status: Coming Soon
    Contact: Laurel Brechtel, 415-600-1654, Email: BrechtLA@cpmcri.org about Study BMS CA209-204

    • Updated July 2015

    Back to top